LALPATHLAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.9
| Stock Code | LALPATHLAB | Market Cap | 22,908 Cr. | Current Price | 1,367 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 43.1 | Book Value | 148 ₹ | Dividend Yield | 0.88 % | ROCE | 29.4 % |
| ROE | 23.1 % | Face Value | 10.0 ₹ | DMA 50 | 1,393 ₹ | DMA 200 | 1,443 ₹ |
| Chg in FII Hold | -3.11 % | Chg in DII Hold | 2.17 % | PAT Qtr | 141 Cr. | PAT Prev Qtr | 113 Cr. |
| RSI | 44.7 | MACD | 9.36 | Volume | 3,01,935 | Avg Vol 1Wk | 2,27,566 |
| Low price | 1,272 ₹ | High price | 1,771 ₹ | PEG Ratio | 1.94 | Debt to equity | 0.08 |
| 52w Index | 19.1 % | Qtr Profit Var | -4.92 % | EPS | 30.3 ₹ | Industry PE | 34.6 |
📊 Dr. Lal PathLabs (LALPATHLAB) demonstrates strong fundamentals with ROE (23.1%) and ROCE (29.4%), supported by low debt-to-equity (0.08). EPS of ₹30.3 reflects earnings strength, and dividend yield of 0.88% adds shareholder value. Quarterly PAT improved (113 Cr → 141 Cr), though profit variation (-4.92%) highlights inconsistency. Valuation is stretched with P/E (43.1) compared to industry average (34.6), while PEG ratio (1.94) suggests growth is already priced in. Technicals remain weak with RSI (44.7), MACD (9.36), and price trading below both 50 DMA (1,393 ₹) and 200 DMA (1,443 ₹).
🎯 Entry Zone: 1,320 ₹ – 1,350 ₹ (near support levels)
📌 Long-Term Holding: Suitable for accumulation with a 2–3 year horizon. Strong fundamentals justify holding, though valuations and weak technicals warrant cautious exposure. Upside potential exists toward 1,450–1,500 ₹ if earnings growth sustains.
Positive
- Strong ROE (23.1%) and ROCE (29.4%) highlight efficiency.
- Low debt-to-equity (0.08) ensures financial resilience.
- EPS of ₹30.3 supports earnings visibility.
- DII holdings increased (+2.17%), showing domestic institutional confidence.
Limitation
- High P/E (43.1) compared to industry average (34.6).
- Negative profit variation (-4.92%) highlights earnings inconsistency.
- Weak technicals with RSI below 50 and price under DMA levels.
- Decline in FII holdings (-3.11%) shows reduced foreign investor confidence.
Company Negative News
- Profitability volatility remains a concern despite sequential PAT growth.
- Weak technical momentum below DMA levels.
Company Positive News
- Quarterly PAT growth (113 Cr → 141 Cr) reflects operational strength.
- DII inflows (+2.17%) highlight domestic institutional support.
- Strong efficiency metrics with low leverage.
Industry
- Industry P/E (34.6) is lower than LALPATHLAB’s 43.1, suggesting premium valuation.
- Diagnostics sector remains resilient, supported by rising healthcare demand and preventive testing trends.
Conclusion
⚡ LALPATHLAB is fundamentally strong with efficient capital use and low debt. Entry around 1,320–1,350 ₹ offers favorable risk-reward. Long-term holding is justified with cautious accumulation, though valuations and weak technicals limit compounding potential. Partial profit booking near 1,450–1,500 ₹ is advisable, with exit below 1,300 ₹ on heavy volume.
This structured HTML report captures Lal PathLabs’ strong fundamentals alongside its valuation risks and technical weakness. If you’d like, I can extend this into a peer benchmarking overlay against other diagnostic players like Metropolis or Thyrocare to highlight relative positioning. Would you like me to prepare that next?